Chest ACCP Career Connection
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spratling, L.
Right arrow Articles by Requa, R. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spratling, L.
Right arrow Articles by Requa, R. K.

Chest, Vol 88, 687-690, Copyright © 1985 by American College of Chest Physicians

ARTICLES

Daily vs alternate day prednisone therapy for stage II sarcoidosis

L Spratling, MF Tenholder, GH Underwood, BL Feaster and RK Requa

Forty-four patients with newly discovered biopsy-proven pulmonary sarcoidosis in roentgenographic stage II (adenopathy and interstitial abnormalities) who also had abnormal pulmonary function (TLC and/or DCO less than 80 percent predicted) were assigned in alternate sequence to either a daily or alternate day prednisone treatment protocol. Both groups showed statistically significant improvement in pulmonary function (TLC, FVC, FEV1, DCO) at three or six months, but there were no significant differences between the two groups. Radiographic adenopathy and interstitial scores (interpreted by blinded readers in random sequence according to a quantitative scale) also showed significant improvement in both groups at three or six months, and again no significant difference was noted between the two groups. Thus, both daily and alternate day prednisone regimens were effective therapy for stage II sarcoidosis. Alternate day therapy may be the treatment of choice for those patients at high risk for significant adverse steroid effects.


This article has been cited by other articles:


Home page
 ThoraxHome page
G J GIBSON
Sarcoidosis: old and new treatments
Thorax, May 1, 2001; 56(5): 336 - 339.
[Full Text]

Home page
 ThoraxHome page
D. M Mitchell and A. Woodcock
Introduction
Thorax, August 1, 1999; 54(90002): S1 - 1.
[PDF]

Home page
 ChestHome page
M. A. Judson
An Approach to the Treatment of Pulmonary Sarcoidosis With Corticosteroids: The Six Phases of Treatment
Chest, April 1, 1999; 115(4): 1158 - 1165.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
B. T. SOCIETY and S. O. C. COMMITTEE
The Diagnosis, Assessment and Treatment of Diffuse Parenchymal Lung Disease in Adults---British Thoracic Society recommendations
Thorax, April 1, 1990; 54(90001): 1S - 28.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by the American College of Chest Physicians.